?

Log in

No account? Create an account

Previous Entry | Next Entry

http://www.independent.co.uk/life-style/health-and-families/health-news/cancer-shock-breakthrough-1710727.html

Ipilimumab is one of a class of drugs called monoclonal antibodies, which stimulate the body's own immune system to fight disease. The experimental treatment is being developed by Bristol-Myers Squibb and Medarex, a US biotech company. The drug is being trialled on malignant melanoma, the most serious form of skin cancer, Hodgkin's disease, lung cancer and prostate cancer. Studies are most advanced in melanoma, where it has been shown to prolong survival in patients with advanced forms of the disease. In the Mayo Clinic study of prostate cancer, researchers say that standard hormone treatment ignited the immune response, and adding ipilimumab was like "pouring gasoline on the pilot light".

Apparently it caused remarkable recession in several men's prostate cancers. During surgery the pathologists were having a hard time finding any remaining cancer cells.

Profile

moon
liveonearth
liveonearth

Latest Month

August 2019
S M T W T F S
    123
45678910
11121314151617
18192021222324
25262728293031

Tags

Powered by LiveJournal.com
Designed by chasethestars